New hope for men with resistant prostate cancer: darolutamide combo tested

NCT ID NCT07538843

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study looks at how well darolutamide (Nubeqa) plus standard hormone therapy works in Chinese men whose prostate cancer has become resistant to earlier treatment but hasn't spread. About 800 men will take part, and researchers will track PSA levels to see if the cancer is controlled. The goal is to understand if this combination can delay cancer progression in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT)
What this could lead to: If successful, this could show that darolutamide plus ADT effectively controls cancer progression in men whose prostate cancer has become resistant to earlier treatments.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. The cancer may still progress despite treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Many locations

Multiple Locations, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.